Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

导出 LinkOut

翻译打印收藏纠错

作者： James,Kalmuk ^[1] ; Jon,Puchalla ^[1] ; Gong,Feng ^[2] ; Anshu,Giri ^[3] ; John,Kaczmar ^[3]

作者单位： 1Department of Internal Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425 USA. ^[1] 2Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425 USA. ^[2] 3Department of Hematology/Oncology, Medical University of South Carolina Walton Research Building, 39 Sabin Street, Charleston, SC 29425 USA. ^[3]

关键词 Checkpoint inhibitors HLH Head and neck squamous cell carcinoma Hemophagocytic Lymphohistiocytosis Immune-related adverse events Pembrolizumab irAEs

DOI 10.1186/s41199-020-0050-3

PMID 32025343

发布时间 2022-04-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancers of the head & neck

2020年5卷

3页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

Cancers of the head & neck

相似文献

Cancers of the head & neck

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

Cancers of the head & neck

相似文献

Cancers of the head & neck

相关期刊

检索历史清除